The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia

Abstract

AbstractThe expansion of acute myeloid leukemia (AML) blasts not only suppresses normal hematopoiesis, but also alters the microenvironment. The interplay of different components of the bone marrow gives rise to altered metabolic states and activates signaling pathways which lead to resistance and impede effective therapy. Therefore, the underlying processes and mechanisms represent attractive therapeutic leverage points for overcoming therapy resistance in AML. Here, we briefly discuss resistance mechanisms based on cell interactions and secreted soluble factors in the hematopoietic niche and provide an overview of niche‐related therapeutic targets currently undergoing preclinical and clinical investigation which may help improve the outcome in AML therapy.